We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+19.15%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.86B
AUM Growth
+$577M
Cap. Flow
+$413M
Cap. Flow %
22.17%
Top 10 Hldgs %
49.85%
Holding
103
New
20
Increased
27
Reduced
19
Closed
9

Top Buys

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$21.4M
2
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$20.5M
3
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
+$16M
4
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$14.4M
5
ADXS
Advaxis Inc
ADXS
+$13.6M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$68.3M
2
TVTX icon
Travere Therapeutics
TVTX
+$21.9M
3
UAM
Universal American Corp
UAM
+$12.1M
4
AMPH icon
Amphastar Pharmaceuticals
AMPH
+$11.1M
5
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 75.61%
2 Technology 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$81.2B
$219M 11.74%
+1,750,000
New +$219M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$167M 8.99%
4,815,807
-2,237,697
-32% -$68.3M
AVDL
3
DELISTED
Avadel Pharmaceuticals
AVDL
$105M 5.67%
4,975,184
+255,225
+5% +$4.58M
HRTX icon
4
Heron Therapeutics
HRTX
$90.9M
$74.7M 4.01%
2,396,681
-411,492
-15% -$7.74M
XBI icon
5
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$71.9M 3.86%
+855,000
New +$66.5M
TVTX icon
6
Travere Therapeutics
TVTX
$5.16B
$71.7M 3.85%
2,162,928
-799,370
-27% -$21.9M
PGNX
7
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$66.8M 3.59%
8,951,169
– –
EBS icon
8
Emergent Biosolutions
EBS
$397M
$58M 3.12%
1,760,519
-50,000
-3% -$1.55M
AEGR
9
DELISTED
Aegerion Pharmaceuticals
AEGR
$54.1M 2.91%
2,852,578
+350,000
+14% +$7.58M
ANGO icon
10
AngioDynamics
ANGO
$567M
$39.3M 2.11%
2,398,527
– –
HZNP
11
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$38.2M 2.05%
1,100,000
+600,000
+120% +$18.3M
RXDX
12
DELISTED
Ignyta, Inc.
RXDX
$34.1M 1.83%
2,256,546
+514,846
+30% +$6.23M
PTX
13
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$30M 1.61%
507,593
+290,760
+134% +$20.5M
ADXS
14
DELISTED
Advaxis Inc
ADXS
$29.5M 1.58%
96,673
+42,940
+80% +$13.6M
BDSI
15
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$28.2M 1.52%
3,544,060
+1,297,661
+58% +$11.2M
ASRT
16
DELISTED
Assertio
ASRT
$25.1M 1.35%
19,457
+7,704
+66% +$10.6M
AMPH icon
17
Amphastar Pharmaceuticals
AMPH
$866M
$24.9M 1.34%
1,417,956
-709,898
-33% -$11.1M
ALR
18
DELISTED
Alere Inc
ALR
$23.9M 1.28%
452,423
– –
NVRO
19
DELISTED
NEVRO CORP.
NVRO
$22.6M 1.21%
+419,559
New +$21.4M
ACGN
20
DELISTED
Aceragen Inc
ACGN
$21M 1.13%
41,688
– –
RPTP
21
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$20.8M 1.12%
+1,319,883
New +$16M
CORI
22
DELISTED
Corium International, Inc.
CORI
$20.6M 1.11%
1,504,762
-231,974
-13% -$2.62M
RIGL icon
23
Rigel Pharmaceuticals
RIGL
$734M
$18.9M 1.01%
587,675
-236,958
-29% -$9.05M
LJPC
24
DELISTED
La Jolla Pharmaceutical Company
LJPC
$18.6M 1%
759,470
+56,000
+8% +$1.15M
QLTI
25
DELISTED
QLT Inc
QLTI
$18.4M 0.99%
4,445,527
+3,300,000
+288% +$12.7M
1
2 3 4 5

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Broadfin Capital held 103 positions worth $1.86B, up 45% from $1.28B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Broadfin Capital deployed $413M of net new capital in Q2 2015, opening 20 new positions and adding to 27 existing holdings. Its largest new stake was NEVRO CORP.: 419,559 shares worth $22.6M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 92% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $68.3M trimmed.

  • Broadfin Capital's largest Q2 2015 buy was NEVRO CORP.: 419,559 shares worth $22.6M.
  • Broadfin Capital added most to Pernix Therapeutics Holdings, Inc. in Q2 2015, an estimated $20.5M increase.
  • Broadfin Capital's biggest Q2 2015 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $68.3M.
  • Broadfin Capital fully exited Universal American Corp in Q2 2015, selling an estimated $12.1M.
  • Broadfin Capital's ten largest holdings make up 50% of its $1.86B portfolio in Q2 2015.
  • Broadfin Capital opened 20 new positions and closed 9 in Q2 2015.
  • Broadfin Capital's portfolio value rose 45% quarter-over-quarter to $1.86B.

Based on Broadfin Capital's 13F filing for Q2 2015, filed 14 Aug 2015.